These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2809278)

  • 1. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser.
    Larocca AP; Leung SC; Marcus SG; Colby CB; Borden EC
    J Interferon Res; 1989 Sep; 9 Suppl 1():S51-60. PubMed ID: 2809278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection and incidence of neutralizing antibodies to interferon-alpha-n1.
    Weck PK; Leventhal BG; Brand C; Finter NB
    J Interferon Res; 1989 Sep; 9 Suppl 1():S37-43. PubMed ID: 2553830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells.
    Abdul-Ahad AK; Galazka AR; Revel M; Biffoni M; Borden EC
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):27-32. PubMed ID: 9287241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I evaluation of a synthetic mutant of beta-interferon.
    Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
    Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High levels of circulating neutralizing antibody in normal animals to recombinant mouse interferon-beta produced in yeast.
    Sedmak JJ; Grossberg SE
    J Interferon Res; 1989 Sep; 9 Suppl 1():S61-5. PubMed ID: 2809279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies in patients with recurrent respiratory papillomatosis treated with lymphoblastoid interferon.
    Thurmond LM; Brand CM; Leventhal BG; Finter NB; Johnston JM
    J Lab Clin Med; 1991 Sep; 118(3):232-40. PubMed ID: 1919296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies.
    Steis RG; Smith JW; Urba WJ; Clark JW; Itri LM; Evans LM; Schoenberger C; Longo DL
    N Engl J Med; 1988 Jun; 318(22):1409-13. PubMed ID: 3367950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.
    Sominanda A; Lundkvist M; Fogdell-Hahn A; Hemmer B; Hartung HP; Hillert J; Menge T; Kieseier BC
    Arch Neurol; 2010 Sep; 67(9):1095-101. PubMed ID: 20837854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
    Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
    Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
    Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
    Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies.
    Gneiss C; Tripp P; Ehling R; Khalil M; Lutterotti A; Egg R; Mayringer I; Künz B; Berger T; Reindl M; Deisenhammer F
    J Neuroimmunol; 2006 May; 174(1-2):174-9. PubMed ID: 16556466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intron A (interferon alfa-2b): clinical overview and future directions.
    Spiegel RJ
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):89-101. PubMed ID: 3532338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo priming effects of interferon-beta ser on NK activity of peripheral blood mononuclear cells in cancer patients.
    Fujimiya Y; Wagner RJ; Groveman S; Sielaff K; Kohsaka T; Nakayama M
    Ther Immunol; 1995 Feb; 2(1):15-22. PubMed ID: 7553067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
    Spiegel RJ; Jacobs SL; Treuhaft MW
    J Interferon Res; 1989 Sep; 9 Suppl 1():S17-24. PubMed ID: 2553829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
    Millonig A; Rudzki D; Hölzl M; Ehling R; Gneiss C; Künz B; Berger T; Reindl M; Deisenhammer F
    Mult Scler; 2009 Aug; 15(8):977-83. PubMed ID: 19465447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
    Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K
    Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential phase II trials of fluorouracil and interferon beta ser with or without sargramostim in patients with advanced colorectal carcinoma.
    Wadler S; Haynes H; Rozenblit A; Hu X; Kaleya R; Wiernik PH
    Cancer J Sci Am; 1998; 4(5):331-7. PubMed ID: 9815298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.